Altre lingue Jiangsu Hengrui Medicine Co., Ltd.

Azioni

600276

CNE0000014W7

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
45,61 ^CNY	+2,96%		+9,43%	+0,84%

26/04	Hengrui Pharma ottiene l'autorizzazione a sperimentare l'iniezione di insulina aspart; azioni in rialzo del 3%	MT
17/04	Jiangsu Hengrui Medicine Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	26/04
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	17/04
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs	11/04
China Approves Clinical Trials for Hengrui Pharmaceuticals' Lupus, Asthma Drugs	10/04
Hengrui Pharma's Units Get Approval to Trial Two Gastric Cancer Drugs	09/04
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	02/04
Hengrui Pharma Gets Nod for Injectable Cancer Drug Trial	27/03
Hengrui Pharma Gets Green Light to Trial Four Cancer Drugs	19/03
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	14/03
Hengrui Pharma Gets Green Light to Trial Tumor Drug Combination	01/03
Hengrui Pharma Gets China Nod to Trial Combo Treatment for Breast Cancer	28/02
US FDA Gives Fast Track Designation to Hengrui Pharma's Lymphoma Drug	23/02
Hengrui Pharma's Unit Gets Nod to Trial Adebelimab Injection	23/02
GSK completes acquisition of Aiolos Bio for up to $1.4 bln	15/02
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	08/02
Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	07/02
MÄRKTE ASIEN/Börsen in China von staatlichen Maßnahmen gestützt	06/02
MÄRKTE ASIEN/China-Börsen von staatlichen Maßnahmen gestützt	06/02
Cancer Drug of Hengrui Pharmaceuticals' Unit Placed in China's List of Breakthrough Therapy Drugs; Shares Climb 4%	05/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Jiangsu Hengrui Medicine Co., Ltd.

Azioni

600276

CNE0000014W7

Altre lingue

Filtri